LEV PHARMACEUTICALS
Lev Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on developing and commercializing therapeutic products for the treatment of inflammatory diseases. Its products include C1-INH that is used for the treatment of hereditary angioedema. The company was founded in 2003 and is based in New York, New York. As of October 21, 2008, Lev Pharmaceuticals, Inc. operates as a subsidiary of ViroPharma Inc.
LEV PHARMACEUTICALS
Industry:
Biotechnology Pharmaceutical Therapeutics
Founded:
2003-01-01
Address:
New York, New York, United States
Country:
United States
Total Employee:
11+
Status:
Active
Total Funding:
41 M USD
Similar Organizations
Resolvyx Pharmaceuticals
Resolvyx Pharmaceuticals develops therapeutics with small molecule lipid mediators for the treatment of inflammatory diseases.
Current Employees Featured
Founder
Investors List
Mast Capital Management
Mast Capital Management investment in Venture Round - Lev Pharmaceuticals
Alexandra Investment Management
Alexandra Investment Management investment in Venture Round - Lev Pharmaceuticals
Rosalind Capital Partners
Rosalind Capital Partners investment in Venture Round - Lev Pharmaceuticals
Emigrant Capital
Emigrant Capital investment in Venture Round - Lev Pharmaceuticals
Southpoint Capital Advisors
Southpoint Capital Advisors investment in Venture Round - Lev Pharmaceuticals
Hound Partners
Hound Partners investment in Venture Round - Lev Pharmaceuticals
More informations about "Lev Pharmaceuticals"
Lev Pharmaceuticals - Crunchbase Company Profile & Funding
Lev Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on developing and commercializing therapeutic products for the treatment of inflammatory diseases. Its products include C1-INH that is used for the treatment of hereditary angioedema.See details»
Lev Pharmaceuticals Company Profile 2024: Valuation, Investors ...
Information on acquisition, funding, investors, and executives for Lev Pharmaceuticals. Use the PitchBook Platform to explore the full profile.See details»
Lev Pharmaceuticals Inc - Company Profile and News
Lev Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the treatment of inflammatory diseases.See details»
Lev Pharmaceuticals - Funding, Financials, Valuation & Investors
Lev Pharmaceuticals is focused on developing therapeutic products for the treatment of inflammatory diseases.See details»
ViroPharma To Acquire Lev Pharmaceuticals - Fierce Biotech
Jul 15, 2008 · Under the terms of the merger agreement, ViroPharma will acquire the outstanding common stock of Lev for $2.25 per share in cash and $0.50 per share in stock ("Upfront …See details»
ViroPharma Incorporated Completes Acquisition Of Lev …
Oct 24, 2008 · ViroPharma Incorporated recently announced it has completed its acquisition of Lev Pharmaceuticals (BULLETIN BOARD: LEVP) following the approval earlier today of the …See details»
Lev Pharmaceuticals - Contacts, Employees, Board Members
Lev Pharmaceuticals has 2 current employee profiles, including Vice President Ira Kalfus. Lev Pharmaceuticals is focused on developing therapeutic products for the treatment of …See details»
Lev Pharmaceuticals - Products, Competitors, Financials, …
Lev Pharmaceuticals was a Healthcare/Pharmaceuticals / Drugs company based in New York, New York. Use the CB Insights Platform to explore Lev Pharmaceuticals's full profile. Lev …See details»
ViroPharma to buy Lev for $442M | Fierce Biotech
Jul 15, 2008 · ViroPharma has forged a deal to buy Lev Pharmaceuticals--a developer focused on developing inflammatory therapies--for $442 million. The deal provides ViroPharma with Lev's …See details»
ViroPharma (VPHM) To Acquire Lev Pharmaceuticals (LEVP) For …
Jul 15, 2008 · ViroPharma Incorporated (Nasdaq: VPHM) and Lev Pharmaceuticals, Inc. (OTCBB: LEVP) announced that the companies have signed a definitive merger agreement under which …See details»
Lev Pharmaceuticals Stock Price, Funding, Valuation, Revenue ...
See Lev Pharmaceuticals funding rounds, investors, investments, exits and more. Evaluate their financials based on Lev Pharmaceuticals's post-money valuation and revenue.See details»
ViroPharma To Acquire Lev Pharmaceuticals
ViroPharma Incorporated and Lev Pharmaceuticals, Inc. recently announced that the companies have signed a definitive merger agreement under which ViroPharma will acquire Lev, a …See details»
Orphan Drugs - 99% Invisible
Nov 13, 2018 · In 2003, Schein started a company called Lev Pharmaceuticals, which would do one thing, and one thing alone: Lev was going to market a drug for a rare disorder called …See details»
Lev Pharmaceuticals - Crunchbase
Lev Pharmaceuticals is focused on developing therapeutic products for the treatment of inflammatory diseases.See details»
For ViroPharma, Acquisition Plan Is Paying Off - TheStreet
Oct 14, 2008 · Lev Pharmaceuticals, a company ViroPharma is planning to buy, received news Friday that U.S. regulators cleared Cinryze to prevent painful attacks that occur in patients with …See details»
Lev Pharmaceuticals, Inc. Initiates Prophylaxis Treatment In
Nov 1, 2005 · Lev Pharmaceuticals initiated its Phase III trial of C1-INH in the first quarter of this year. The first part of the study, which is ongoing, is designed to examine the efficacy and …See details»
Nanofiltered C1 Inhibitor Concentrate for Treatment of Hereditary ...
Aug 5, 2010 · We conducted two randomized trials to evaluate nanofiltered C1 inhibitor concentrate in the management of hereditary angioedema. The first study compared …See details»
Lev Pharmaceuticals | Insights
Generic drugs approved in 2022 saved patients nearly $19bn in their first year on the market, thanks in large part to follow-ons of Sumitomo Dainippon Pharma’s psychiatric drug Latuda …See details»
Judson A. Cooper - Co-founder @ Lev Pharmaceuticals - Crunchbase
Judson A. Cooper is the Co-founder at Lev Pharmaceuticals. Judson A. Cooper is the Board Member at Osteal Therapeutics. There is no recent news or activity for this profile.See details»